Penumbra (MEX:PEN) PE Ratio without NRI: 64.65 (As of Jun. 28, 2026) — 64% Below Median


MEX:PEN Penumbra Inc MEX:PEN
89 GF Score
Price MXN4,775.70
GF Value MXN4,994.10
! 2 Warning Signs
View Full Analysis

What is Penumbra PE Ratio without NRI?

Penumbra MEX:PEN 89 PE Ratio without NRI is 64.65 as of Jun. 28, 2026, which is 64% below its 10-year median of 177.66. GuruFocus rates MEX:PEN with a GF Score™ of 89/100 and a GF Value™ of MXN4,994.10. The stock has 2 warning signs investors should review. Among 447 Medical Devices & Instruments companies, Penumbra ranks worse than 89.26% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-06-28), Penumbra's share price is MXN4775.70. Penumbra's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was MXN73.69. Therefore, Penumbra's PE Ratio without NRI for today is 64.65.

During the past 13 years, Penumbra's highest PE Ratio without NRI was 137335.00. The lowest was 59.37. And the median was 177.66.

Penumbra's EPS without NRI for the three months ended in Mar. 2026 was MXN14.79. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was MXN73.69.

As of today (2026-06-28), Penumbra's share price is MXN4775.70. Penumbra's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN79.51. Therefore, Penumbra's PE Ratio (TTM) for today is 59.88.

Warning Sign:

Penumbra Inc stock PE Ratio (=72.96) is close to 1-year high of 79.48.

During the past years, Penumbra's highest PE Ratio (TTM) was 2108.56. The lowest was 54.39. And the median was 291.09.

Penumbra's EPS (Diluted) for the three months ended in Mar. 2026 was MXN14.79. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN79.51.

Penumbra's EPS (Basic) for the three months ended in Mar. 2026 was MXN14.97. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was MXN80.25.


Penumbra  (MEX:PEN) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Penumbra PE Ratio without NRI Related Terms


Penumbra PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Penumbra's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Penumbra PE Ratio without NRI Chart

Penumbra Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 416.41 1,390.38 93.61 106.97 80.97

Penumbra Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 105.57 75.26 66.14 80.97 81.48

MEX:PEN vs GMED, PODD, BRKR: PE Ratio without NRI Comparison

For the Medical Devices subindustry, Penumbra's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Penumbra PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Penumbra's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Penumbra's PE Ratio without NRI falls into.


MEX:PEN
89GF Score
Penumbra Inc MEX:PEN
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Penumbra PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Penumbra's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=4775.70/73.872
=64.65

Penumbra's Share Price of today is MXN4775.70.
Penumbra's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN73.69.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 64.65 mean?
Penumbra (MEX:PEN) has a PE Ratio without NRI of 64.65 as of Jun. 28, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Penumbra and its competitors. This is 64% below median its historical median of 177.66. Over the past decade, Penumbra's PE Ratio without NRI has ranged from 59.37 to 137,335.00. According to the industry distribution chart, Penumbra ranks #399 out of 447 companies in the Medical Devices & Instruments industry, placing it in the top 89.3%.
Is Penumbra's PE Ratio without NRI too high?
Penumbra's current PE Ratio without NRI of 64.65 is 64% below median its 10-year median of 177.66. Over the past 10 years, this metric has ranged from a low of 59.37 to a high of 137,335.00. The Medical Devices & Instruments industry median PE Ratio without NRI is 23.16. Penumbra's value of 64.65 is 179.1% above this industry median. Based on the distribution chart, Penumbra ranks #399 out of 447 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Penumbra has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Penumbra's PE Ratio without NRI compare to GMED and PODD?
According to the Medical Devices & Instruments industry distribution chart, Penumbra ranks #399 out of 447 companies for PE Ratio without NRI. This places Penumbra in the lower half of its industry. The industry median PE Ratio without NRI is 23.16. Penumbra's value of 64.65 is 179.1% above this benchmark. Historically, Penumbra's own PE Ratio without NRI has ranged from 59.37 to 137,335.00 over the past decade. While the company's 10-year median is 177.66 vs. the industry median of 23.16, Penumbra has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Medical Devices & Instruments company?
The median PE Ratio without NRI among Medical Devices & Instruments companies is 23.16, based on 447 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Penumbra's current PE Ratio without NRI of 64.65 is 179.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Penumbra and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio without NRI is 23.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Penumbra's current PE Ratio without NRI is 64.65, which is 64% below median its own 10-year median of 177.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Penumbra stock overvalued right now?
Penumbra (MEX:PEN) has a current PE Ratio without NRI of 64.65. The stock's GF Value™ is MXN4,994.10, compared to a current price of MXN4,775.70 — trading 4.4% below its estimated fair value. The current PE Ratio without NRI is 64.65, which is 64% below median its 10-year median of 177.66 and 179.1% above the Medical Devices & Instruments industry median of 23.16. Penumbra's overall GF Score™ is 89/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Penumbra (MEX:PEN), the current PE Ratio without NRI is 64.65 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Penumbra (MEX:PEN) Overvalued in 2026?

Based on GuruFocus' analysis, Penumbra stock appears to be undervalued. The current stock price of MXN4,775.70 is trading 4.4% below its estimated GF Value™ of MXN4,994.10.

Key valuation signals for MEX:PEN:

  • PE Ratio without NRI: 64.65 (64% below median its 10-year median of 177.66)
  • GF Value™: MXN4,994.10 vs. price of MXN4,775.70 (4.4% below fair value)
  • GF Score™: 89/100 with 2 warning signs
  • Industry Position: 179.1% above the Medical Devices & Instruments median (#399 of 447)

No single metric tells the full story. See the MEX:PEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Penumbra Business Description

Other Exchanges PEN:USA0P8:Germany
Address 1310 Harbor Bay Parkway, One Penumbra Place, Alameda, CA, USA, 94502
Penumbra Inc is a thrombectomy company focused on developing technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. Its portfolio includes Computer-Assisted Vacuum Thrombectomy (CAVT), which is designed to remove blood clots throughout the body. The company offers products such as the Artemis Neuro Evacuation Device (used for surgical removal of fluid and tissue from the ventricles and cerebrum), Indigo System, Penumbra System Reperfusion Catheter, LANTERN Delivery Microcatheter, Penumbra Smart Coil, and ACE Reperfusion Catheters, among others. The company generates maximum revenue from the sale of its products in the United States, followed by international markets.
89GF Score

Get the complete analysis for MEX:PEN

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN4,775.70
Price
MXN4,994.10
GF Value